1 of 1
Story summary
- The BMJ study finds that glucagon-like peptide-1 (GLP-1) drugs, used for diabetes and obesity, may reduce the risk of multiple substance use disorders among over 600,000 U.S. Veterans Affairs patients.
- The study reports a 50% reduction in drug-related deaths and a 31% decrease in emergency visits among those with existing disorders.
- Experts say randomized trials are needed to confirm the findings and determine optimal treatment protocols.
